Prosecution Insights
Last updated: April 19, 2026
Application No. 18/249,829

NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Non-Final OA §102
Filed
Apr 20, 2023
Examiner
RICCI, CRAIG D
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Icahn School Of Medicine AT Mount Sinai
OA Round
1 (Non-Final)
54%
Grant Probability
Moderate
1-2
OA Rounds
3y 3m
To Grant
99%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allow Rate
607 granted / 1131 resolved
-6.3% vs TC avg
Strong +52% interview lift
Without
With
+52.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
65 currently pending
Career history
1196
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
40.6%
+0.6% vs TC avg
§102
17.2%
-22.8% vs TC avg
§112
20.7%
-19.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1131 resolved cases

Office Action

§102
DETAILED ACTION Notice of AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without specifying traverse of Group I in the reply filed on 12/05/2025 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). The requirement is still deemed proper and is therefore made FINAL. Claims 4-9, 12, 14 and 16-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant’s election without specifying traverse of a single species in the reply filed on 12/05/2025 is also acknowledged. Applicant indicates that the elected species reads upon claims 1-3. However, the elected species also appears to read on Formula I(B) as recited by claim 13 wherein X is S, R2-R6 are H, n is 6, m is 1, p is 0, and r is 0. As such, the elected species is determined to read upon claims 1-3 and 13, and claims 10-11 and 15 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Expansion of Election of Species Requirement Applicant’s elected species: PNG media_image1.png 190 696 media_image1.png Greyscale reads upon claims 1-3 and 13. The elected species has been searched and is deemed to be free of the prior art and non-obvious. Accordingly, the search has been expanded as called for under current Office Markush practice – a compound-by-compound search – to include a single additional species (M.P.E.P. § 803.02). That species is PNG media_image2.png 164 550 media_image2.png Greyscale wherein, in Formula I, X is S; Y is NH; W is CH2; R1 is substituted aryl; R2-R6 are independently hydrogen; R7 is substituted aryl; R8 is hydrogen; n is 1 and m is 1 – which reads on claim 1. A rejection to that claim follows. Since the search has not been expanded beyond the single additional species identified above, claims 2-3 and 13, which are directed to the elected species but which do not include the single additional species, are objected to as indicated below, and have not been further examined. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claim 1 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Chowdhury et al (WO 2008/101029). Claim 1 is drawn to a compound of Formula I which embraces the following compound species PNG media_image2.png 164 550 media_image2.png Greyscale wherein X is S; Y is NH; W is CH2; R1 is substituted aryl; R2-R6 are independently hydrogen; R7 is substituted aryl; R8 is hydrogen; n is 1 and m is 1. Chowdhury et al teach the instantly claimed compound (Page 80, Synthetic Example 3). Accordingly, claim 1 is anticipated. Claim Objections Claims 2-3 are objected to as depending from a rejected base claim. Claims 2-3 and 13, which are directed to the elected species but which do not include the single additional species, are further objected to as containing non-elected subject matter, and have not been further examined. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CRAIG D RICCI whose telephone number is (571) 270-5864. The examiner can normally be reached on Monday through Thursday, and every other Friday, 7:30 am - 5:00 pm ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bethany Barham can be reached on (571) 272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CRAIG D RICCI/Primary Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Apr 20, 2023
Application Filed
Dec 25, 2025
Non-Final Rejection — §102
Jan 14, 2026
Examiner Interview Summary
Jan 14, 2026
Interview Requested
Jan 14, 2026
Applicant Interview (Telephonic)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12570673
C-MYC PROTEIN INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF
2y 5m to grant Granted Mar 10, 2026
Patent 12569440
SOLID FORMULATION OF A 1,2,4-OXADIAZOLE DERIVATIVE
2y 5m to grant Granted Mar 10, 2026
Patent 12569530
TANNIN-BASED ANTIPROLIFERATIVE PHARMACEUTICAL
2y 5m to grant Granted Mar 10, 2026
Patent 12552776
CRYSTALLINE FORMS
2y 5m to grant Granted Feb 17, 2026
Patent 12544356
COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
54%
Grant Probability
99%
With Interview (+52.3%)
3y 3m
Median Time to Grant
Low
PTA Risk
Based on 1131 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month